**
In 2021, the FDA approved Ozempic, a groundbreaking drug now classified as a GLP-1 agonist, for weight loss. This marked a new era in the treatment of obesity but has since expanded its potential to treat other conditions. Now, researchers are exploring whether these drugs could tackle cognitive issues like Alzheimer’s disease and addiction.
GLP-1 drugs have shown promising results in reducing risks for various health outcomes, including neurodegenerative disorders, substance use disorders, and cardiovascular conditions. A recent study examined the benefits and side effects of GLP-1 drugs across 24 possible health outcomes. The findings revealed significant reductions in risks for conditions like Alzheimer’s disease, dementia, and opioid-related issues. However, they also highlighted increased risks for gastrointestinal, kidney, and pancreas issues.
The drug’s ability to lower blood clotting risks is particularly notable, with studies suggesting it may reduce the risk of infections such as pneumonia. This dual benefit—reducing cardiovascular death risks while lowering infection risks—makes GLP-1 drugs a potential game-changer in treating conditions tied to COVID-19 and other viruses.
Despite their therapeutic potential, GLP-1 drugs come with challenges, including common side effects like nausea and high costs that drive patients to discontinue treatment. Addressing these issues will be crucial for maximizing the benefits of GLP-1 drugs while minimizing risks.
Source: https://theconversation.com/ozempic-and-similar-weight-loss-drugs-may-lower-risk-of-42-health-conditions-but-also-pose-risks-244243